Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis

Hepatology

Volumn 29, Issue 1, 1999, Pages 39-43

  Bonnand, Anne Marie ^a   Heathcote, E Jenny ^b   Lindor, Keith D ^c   Poupon, Renée Eugénie ^a  

^a INSERM   (France)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032929133     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290140     Document Type: Article

References (28)

1. Poupon RE, Balkau B, Eschwège E, Poupon R, and the UDCA-PBC Study-Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
2. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh P, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
3. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of Ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;19:1149-1156.
4. Combes B. Carithers R, Maddrey WC, Li D, McDonald MF, Wheeler DE, Eidenbdrot EH, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholate in primary biliary cirrhosis. HEPATOLOGY 1995;22:759-766.
5. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
6. Shapiro JM, Smith H, Schaffner E Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979;20:137-140.
7. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7
8. Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, Portmann B, Doniach D, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89:1084-1091.
9. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. HEPATOLOGY 1989;10:1-7.
10. Consensus statement on indications for liver transplantation: Paris, June 22-23, 1993. HEPATOLOGY 1994;20:63S-68S.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete samples. J Am Stat Assoc 1958;53:457-481.
12. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
13. Raedsch R, Stiehl A, Walker S, Theilman L, Kommerell B. Effects of ursodeoxycholic acid and ursodeoxycholic acid plus colchicine in primary biliary cirrhosis: a double-blind pilot study. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Dordrecht: Kluwer Academic Publishers, 1991:301-304.
14. Almasio P, Provenzano G, Battezzati PM, Podda M, Todros L, Rosina F, Saccocio G, et al. The Italian multi-centre randomized controlled trial of ursodeoxycholic acid vs ursodeoxycholic acid plus colchicine in symptomatic primary biliary cirrhosis [Abstract]. HEPATOLOGY 1994;20:267.
15. Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, Sato C. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J Hepatol 1996;24:88-94.
16. Poupon RE, Huet PM, Poupon R, Bonnand A-M, Tran van Nhieu J, Zafrani ES, and the UDCA-PBC Study Group. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;24;1098-1103.
17. Buscher H-P, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol 1993;18:19-14.
18. Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. HEPATOLOGY 1995;22:1158-1162.
19. Van Steenbergen W, Sciot R, Van Eyken P, Desmet V, Fevery J. Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis. Acta Clin Belg 1996;51:8-18.
20. Gonzales-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997;27:143-149.
21. Wolfhagen FHJ, van Buuren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisolone in primary biliary cirrhosis. Neth J Med 1994;44:84-90.
22. Leuschner M, Gültdütuna S, You T, Hübner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996;25:49-57
23. Van Hoogstraten HJF, Wolfhagen FHJ, Van Berge Henegouwen GP, Schalm SW, ten Kate FJW, Hop WCJ, Van Buuren HR, et al. Combined bile acid-immunosuppressive therapy for primary biliary cirrhosis. Results of a 1-year multicentre, placebo controlled study [Abstract]. HEPATOLOGY 1996;24:168.
24. Leuschner U, Maier KP, Güldütuna S, Parté-Peterhans S, Leuschner M. Ursodeoxycholic acid in combination with prednisolone or budenoside in the therapy of primary biliary cirrhosis. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile Acids in Hepatobiliary Diseases. Basic Research and Clinical Application. Dordrecht: Kluwer Academic Publishers, 1997:299-302.
25. Jorgensen RA, Dickson ER, Hofmann AE, Rossi S, Lindor KD. Characterization of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995;36:935-938.
26. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rourke K, Bailey RJ, Blendis LM, Ghent CN, et al. Is the Mayo model for predicting survival useful after introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? HEPATOLOGY 1996;23:1148-1153.
27. Lindor KD, Therneau TM, Hermans JE, Dickson ER. Mayo risk score accurately predicts patient outcome with ursodeoxycholic acid treatment of primary biliary cirrhosis [Abstract]. HEPATOLOGY 1996;24:167.
28. Jones DEJ, James OFW, Bassendine ME Ursodeoxycholic acid therapy in primary biliary cirrhosis. [Comments]. HEPATOLOGY 1995;21:1469-1473.